A Look Into Bristol-Myers Squibb’s Debt
Over the past three months, shares of Bristol-Myers Squibb Inc. (NYSE:BMY) rose by 2.13%. Before we understand the importance of debt, let's look at how much debt Bristol-Myers Squibb has.
SELLAS Life Sciences’ GPS Combo Therapy Shows Overall Survival Of 18 Months In Pretreated Ovarian Cancer Patients
SELLAS Life Sciences Group Inc (NASDAQ:SLS) announced confirmatory topline data from the final analysis of results from its Phase 1/2 trial…
After FDA, European Agency Limits Use Of Certain JAK Inhibitors Amid Safety Concerns
The European Medicine Agency’s safety committee recommended that a group of JAK inhibitors for chronic inflammatory disorders be only used…
Analyst Sees Market Potential For Arcellx Multiple Myeloma Candidate, Sees 50% Upside In Stock
Needham initiated coverage on Arcellx Inc (NASDAQ:ACLX) with a Buy rating and a price target of $31. Arcellx’s lead program and main…
Wingstop To Rally Around 13%? Plus This Analyst Cuts PT On Cano Health By 50%
Wedbush boosted the price target on Wingstop Inc. (NASDAQ: WING) from $157 to $177. Wedbush analyst Nick Setyan maintained an Outperform rating on the stock. Wingstop shares rose 0.8% to $156.66 on Thursday.
Morgan Stanley Maintains Underweight on Bristol-Myers Squibb, Lowers Price Target to $60
Morgan Stanley analyst Terence Flynn maintains Bristol-Myers Squibb (NYSE:BMY) with a Underweight and lowers the price target from $61 to $60.
This Is What Whales Are Betting On Bristol-Myers Squibb
A whale with a lot of money to spend has taken a noticeably bullish stance on Bristol-Myers Squibb.
Looking at options history for Bristol-Myers Squibb (NYSE:BMY) we detected 17 strange trades.
New Zeposia Data Highlight COVID-19 Outcomes And Preservation Of Long-Term Cognitive Function From Separate Analyses In Patients With Relapsing Forms Of Multiple Sclerosis
Retrospective analyses from the Phase 3 DAYBREAK open-label extension study showed more than 90% of participants who received Zeposia mounted a serologic response to COVID-19 vaccination
All adverse
Bristol Myers Squibb Adjusts 2022 GAAP EPS Guidance Primarily Due To The Acquisition Of Turning Point And Reaffirming Non-GAAP EPS Guidance; Reaffirms Non-GAAP EPS Guidance
Financial Guidance
Bristol Myers Squibb is adjusting its 2022 GAAP line-item guidance as follows:
Adjusting GAAP EPS guidance primarily due to the acquisition of Turning Point and reaffirming